Unlock the transformative power of GLP-1 based obesity drugs with your guides, Clem Miller and Steve Davenport, as we navigate their remarkable impact on healthcare and investment landscapes alike. Prepare to be enlightened on the dual benefits these treatments offer for diabetes and obesity, and the industry titans leading the charge—Novo Nordisk and Eli Lilly. We've dissected the science, sifted through financial forecasts, and even charted the course for potential investors looking to capitalize on this medical revolution. 

The conversation doesn't stop at the pharmacy counter; we delve into the complex web of obesity, genetics, and the monumental societal shifts these drugs could instigate. We also unpack the intricate dance between health and financial wellness, offering actionable insights for investing in pharmaceutical stalwarts and rising stars. Tune in and arm yourself with the acumen to navigate both the health advances reshaping our future and the financial opportunities they present.

Straight Talk for All - Nonsense for None


Please check out our other podcasts:

https://skepticsguidetoinvesting.buzzsprout.com